Myocardial positron emission computed tomographic images obtained with fluorine-18 fluoro-2-deoxyglucose predict the response of idiopathic dilated cardiomyopathy patients to beta-blockers

J Am Coll Cardiol. 2004 Jan 21;43(2):224-33. doi: 10.1016/j.jacc.2003.09.025.

Abstract

Objectives: The aim of this study was to elucidate whether the response of idiopathic dilated cardiomyopathy (DCM) patients to beta-blockers can be predicted by positron emission tomography with fluorine-18 fluoro-2-deoxyglucose (FDG-PET).

Background: Patients with DCM often have a poor prognosis, and it is important to predict their response to beta-blocker therapy, which may be effective in DCM. However, no accurate methods of predicting their response have been available.

Method: In 22 DCM patients with reduced left ventricular (LV) systolic function, FDG-PET was performed. Uptake in the LV after glucose loading was evaluated based on the average global percent uptake of the injected dose (G%ID) and the coefficient of variance (CV) in 24 segments of the LV. Uptake during fasting was evaluated semiquantitatively on the basis of the total uptake score. The beta-blocker was administered, and LV function was monitored by echocardiography. The histologic findings were assessed in the 18 patients who underwent endomyocardial biopsy.

Results: The beta-blocker was effective in the majority of patients whose G%ID after glucose loading was >0.7%, and the sensitivity and specificity of G%ID as a predictor of beta-blocker efficacy were 83.3% and 90.0%, respectively. Percent CV did not predict efficacy. Four groups, defined on the basis of the FDG uptake score during fasting and G%ID after glucose loading, had distinctive histologic findings and outcomes.

Conclusions: It has been shown that FDG-PET is a good predictor for the effectiveness of beta-blockers.

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Adult
  • Cardiomyopathy, Dilated / diagnostic imaging*
  • Cardiomyopathy, Dilated / drug therapy*
  • Female
  • Fluorodeoxyglucose F18*
  • Heart Function Tests / methods
  • Humans
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Radiopharmaceuticals*
  • Tomography, Emission-Computed / methods*
  • Treatment Outcome
  • Ventricular Dysfunction, Left / diagnostic imaging
  • Ventricular Dysfunction, Left / drug therapy

Substances

  • Adrenergic beta-Antagonists
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18